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Glaucoma is a neurodegenerative disorder in 
which a variety of complicated mechanisms lead 
to retinal ganglion cell (RGC) apoptosis and 
death. According to various theories, factors 
including elevated intraocular pressure (IOP) 
and vascular dysregulation primarily contribute 
to the initial insult during glaucomatous atrophy 
in the form of obstruction of axoplasmic flow 
within RGC axons, alteration in optic nerve 
microcirculation at the level of lamina and 
changes in the laminar glial and connective 
tissues. Deprivation of neurotrophic factors, such 
as the brain-derived neurotrophic factor, and 
release of a large number of neurotoxic agents 
within the retina, including glutamate, nitric 
oxide and free radicals, are the consequences 
of the above-mentioned events.
Currently, IOP reduction is the only proven 
clinical therapy available for treatment of 
glaucoma. Nevertheless, signs of progression 
can be seen in many patients despite well-
controlled IOP. In addition, glaucomatous optic 
neuropathy (GON) has even been observed in 
patients with “normal” IOP. Therefore, the 
pathophysiology of glaucoma and particularly 
normal tension glaucoma is probably beyond 
IOP alone. Studies on low pressure glaucoma 
have demonstrated that in most patients higher 
intraocular pressure is unrelated to poor visual 
fields. 
 During the past decade, most studies 
more focused on discovering neuroprotective 
treatments along with IOP lowering medications 
in order to prevent ganglion cell death or even 
reverse the process of cell death. Neuroprotection 
aims at blocking primary destructive events 
affecting RGCs or optic nerve fibers, enhancing 
RGC or optic nerve fiber survival mechanisms 
and finally repairing damage occurring during 
the progressive, secondary stage of the injury.
 The idea of using neuroprotective treatment 
for management of glaucoma arose from the 
successful results of employing neuroprotective 
drugs for treatment of certain neurodegenerative 
disorders of the central nervous system (CNS) 
such as Alzheimer’s and Parkinson’s disease. 
Recent studies have elucidated strong links 
between mechanisms of cell death in Alzheimer’s 
disease and glaucoma.
Glaucoma is a chronic and slowly progressive 
disease, therefore assessment of the efficacy of 
these drugs is a difficult task and requires a 
long time to be proven. Certain IOP lowering 
medications, such as brimonidine and betaxolol 
have been suggested to possess neuroprotective 
effects. Recently, the low pressure glaucoma 
study group released the results of comparing 
brimonidine with timolol with average follow-
up of 30 months. This study showed that patients 
treated with brimonidine were less likely 
(9%) to experience visual field progression as 
compared to subjects treated with timolol (39%). 
IOP reduction was not signiﬁcantly different 
between patients assigned to brimonidine or 
timolol. Although in this study brimonidine, at 
least indirectly, demonstrated neuroprotective 
properties, its mechanism of action is not yet 
fully understood.
There are other promising medical 
approaches for glaucoma neuroprotection which 
are briefly discussed below: 
Glutamate antagonists: Glutamate is one of 
the major neurotransmitters in the CNS and 
retina and elevated levels have been reported 
in glaucoma. This transmitter may facilitate 
RGC apoptosis by activation of N-methyl 
D-aspartate receptors (NMDA), resulting in 
calcium influx into RGCs and disruption of the 
cell wall. Memantine is an anatagonist of NMDA 
which had earlier been proven to be effective 
in Alzheimer’s and Parkinson’s diseases. 
Although animal studies confirmed that this News
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drug protects injured neural cells from death, 
phase III clinical trials on glaucoma in humans 
failed to demonstrate any clinical benefit. The 
study showed that glaucoma progression was 
significantly slower in patients receiving higher 
doses of memantine as compared to patients 
receiving lower doses of the medication, but 
there was no significant benefit when compared 
to patients receiving placebo.
  Neurotrophins: The brain-derived 
neurotrophic factor (BDNF) and ciliary derived 
neurotrophic factor (CNTF) have been found to 
be decreased in glaucoma. These factors suppress 
the intrinsic apoptotic process and activate 
survival signals. Several investigators are now 
exploring the use of gene transfer methods to 
deliver neurotrophic factors. Encapsulated cell 
technology helps to implant cells that have been 
genetically modified to produce neurotrophic 
factors.
Anti inflammatory agents: Recently 
researchers have investigated the immune 
system as a means of providing neuroprotection 
against neuronal damage. Cop-1, otherwise 
known as glatiramer acetate, copolymer-1 and 
copax-1, is a synthetic, random oligopeptide 
composed of amino acids tyrosine, glutamate, 
lysine, and alanine. Cop-1 is a Food and Drug 
Administration (FDA) approved drug for 
treatment of multiple sclerosis. It is a low affinity 
antigen and can evoke both active and passive 
T-cell mediated immune responses at various 
sites of injury. It has been demonstrated that 
Cop-1 reduces damage caused by mechanical 
injury to the optic nerve or intravitreally 
administered glutamate. Another study reported 
that vaccination with Cop-1 leads to significant 
reduction in RGC death in rat models of ocular   
hypertension. 
Antioxidants: It is hypothesized that oxidative 
stress can cause RGC death by damaging the 
trabecular meshwork, the optic nerve head 
and the retina. Targets of oxidative stress 
relevant to the development of GON are most 
probably the mitochondria. Reduced levels of 
the antioxidant agent glutathione and increased 
serum lipid peroxidation products have been 
identified in patients with primary open angle 
glaucoma. Antioxidants such as vitamin C, 
vitamin E and Ginkgo biloba extract have been 
shown to improve visual fields in patients with 
glaucoma but there is still no strong evidence 
or long term studies to confirm this idea. 
Melatonin (N-acetyl-5-methoxytryptamine) is 
an indoleamine, secreted by the pineal gland, 
which exerts antioxidant properties. Melatonin 
has been shown to neutralize free radicals and 
activate some antioxidative enzymes; it can 
therefore be categorized under neuroprotective 
agents. 
Mitochondrial augmentation: Mitochondrial 
dysfunction has been implicated in neuronal 
apoptosis and shown to play a role in experimental 
glaucoma. One in vitro study provided evidence 
that mitochondrial dysfunction accompanying 
RGC death may be induced by glaucoma-related 
stimuli such as tumor necrosis factor (TNF)-α 
and hypoxia. The dopaminergic agent, GLC756, 
has recently been shown to inhibit TNF-α release 
from activated rat mast cells, suggesting a 
potential role for glaucoma neuroprotection. 
Coenzyme Q10 (CoQ10) is a cofactor which 
plays a crucial role in energy production via 
the mitochondrial electron transport chain and 
also has strong antioxidant properties.
Stem cells: Several potential applications 
of stem cells for neuroprotection have been 
explored. Transplanted mesenchymal stem/
stromal (MSC) cells have demonstrated 
significant neuroprotection in a rat model of 
glaucoma. These cells can be isolated from 
a variety of tissues including the adult bone 
marrow and may have the potential to trans-
differentiate into neural cells. However, in order 
for stem cells to be successful, their use must 
be coupled with mechanisms by which newly 
transplanted RGCs can extend their axons to 
appropriate structures within the brain.
Neuroprotective interventions are 
promising in the treatment of glaucoma as 
adjunctive therapy to conventional IOP lowering 
medications. There are animal studies with 
promising results in protecting neuronal cells 
but no longitudinal study in human subjects 
has yet proven these observations. Better 
understanding of the pathophysiology and 
mechanisms of glaucoma can help investigators 
find new modalities of treatments in the future.News
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